PetVivo Holdings filings document material events for a Nevada corporation operating through PetVivo Animal Health and PetVivo AI. Recent Form 8-K reports cover subscription agreements, unregistered equity sales, restricted common stock, warrants, unit issuances, and Regulation D exemptions tied to private financing activity.
The filing record also includes Regulation FD investor-presentation exhibits and governance disclosures under Item 5.02, including director resignations and changes in board size. These documents provide formal disclosure around the company’s capital structure, warrant terms, board composition, and public-company reporting status as an emerging growth company.
At PetVivo Holdings, Inc. (PETV), a corporation owned by Chief Financial Officer Garry N. Lowenthal received a grant of 10,000 restricted common shares on October 21, 2026, as compensation for his past performance. On October 23, 2026, the corporation transferred 7,500 restricted common shares to a third party under a Stock Transfer Agreement.
PetVivo Holdings, Inc. reported that a corporation owned by Chief Executive Officer and director John Lai received a grant of 65,000 restricted common shares on October 21, 2026. The shares were reported at $0.68 per share, and the corporation’s reported post-transaction position was 2,478,163 shares. The award was described as compensation for Lai’s past performance.
PetVivo Holdings, Inc. (PETV) reports that A.L. Sarroff Fund, LLC, a ten percent owner, purchased 78,855 common shares in 14 transactions from October 13, 2026, through October 16, 2026. Direct purchases reported for the fund were 3,000 and 2,000 shares at $0.70 on October 16, 2026; 4,000 at $0.70 and 4,286 at $0.72 on October 14, 2026; and 9,000 at $0.68 plus two 4,000-share purchases at $0.70 on October 13, 2026. Alan L. Sarroff is the fund’s Chief Executive Officer and Managing Member.
Indirect holdings identified as held by Eileen Sarroff, Alan L. Sarroff’s spouse, include 6,969 shares at $0.69, 3,600 at $0.70, three separate 6,000-share purchases at $0.70, and another 6,000 at $0.7487 on October 16, 2026; two 10,000-share purchases at $0.74 were reported on October 15, 2026. No Rule 10b5-1 plan is reported.
PetVivo Holdings, Inc. (PETV) reported a Board change effective September 22, 2026, with the resignation of director Diane Levitan, which the company states did not result from any disagreement regarding operations, policies or practices. The Board simultaneously appointed Jaime K. Pickett, DVM, MBA, to fill the vacancy, keeping the Board at six directors. Dr. Pickett is a veterinary healthcare executive and entrepreneur with more than 20 years of experience in animal health, multi-site operations, corporate strategy and product commercialization, including leadership over more than 55 pet resorts and veterinary hospitals and teams of over 100 veterinary professionals. She will initially serve as a non-employee director with compensation consistent with other non-employee directors, and the company notes there are no related-party transactions or family relationships requiring disclosure.
PetVivo Holdings, Inc. (PETV) reported a Board change, with director Joseph Jasper resigning effective September 22, 2026, and life sciences executive Michael K. Handley appointed the same day to fill the resulting vacancy, keeping the Board at six directors. The company states that Mr. Jasper’s resignation was not due to any disagreement regarding operations, policies or practices.
Mr. Handley brings more than 25 years of biotechnology, pharmaceutical and medical device experience, including raising over $700 million in capital, supporting over 80 global product launches, and involvement in transactions exceeding $4 billion in aggregate value. He will initially serve as a non-employee director, receiving compensation consistent with other non-employee directors, prorated for his service period, and there are no related-party transactions or family relationships requiring disclosure.
PetVivo Holdings, Inc. (PETV) director Robert James Rudelius reported acquiring additional Common Stock on September 18, 2026. He received 2,000 shares at $0.72 per share and 1,497 shares at $0.75 per share, for a total of 3,497 shares, through open-market transactions. The filing also notes 21,000 shares of Common Stock held indirectly through a corporation, representing an existing position. No Rule 10b5-1 trading plan is reported.
PetVivo Holdings, Inc. (PETV) received an amended Schedule 13D (Amendment No. 2) from A.L. Sarroff Fund, LLC, Alan Sarroff, and Eileen Sarroff reporting their beneficial ownership of the company’s common stock.
The reporting group states beneficial ownership of 16,940,839 shares of common stock, representing 38.2% of the class, based on 37,950,495 shares outstanding as of August 14, 2026 and assuming the exercise of warrants for 6,442,508 shares. They acquired their position for investment through open market purchases and private placements using personal funds, and indicate they may increase or decrease their economic exposure over time, including through derivatives, while currently disclosing no specific plans regarding corporate actions listed in the Schedule 13D items.
PetVivo Holdings, Inc. (PETV) reported that A.L. Sarroff Fund, LLC, a ten percent owner, purchased a total of 58,602 shares of Common Stock in open-market or private transactions between August 27 and September 14, 2026 at prices around $0.68 per share.
Some shares are held directly by A.L. Sarroff Fund, LLC, over which Alan L. Sarroff is deemed to have sole voting and dispositive power, and others are held indirectly through Mr. Sarroff’s spouse, Eileen Sarroff.
PetVivo Holdings, Inc. (PETV) reported that its Chief Financial Officer, Garry N. Lowenthal, indirectly acquired securities through a corporation he owns. On September 8, 2026, a warrant covering 31,250 shares of common stock was reported as converted, and the related corporation acquired 31,250 shares of common stock at $0.80 per share in connection with a private placement investment pursuant to a subscription agreement. Following this acquisition, the corporation associated with Lowenthal held 985,131 shares of PetVivo common stock indirectly, and 31,250 common stock warrants were reported as held indirectly after the derivative transaction. No Rule 10b5‑1 trading plan is reported for these transactions.
PetVivo Holdings, Inc. (PETV) reports that Chief Executive Officer and director John Lai acquired 31,250 shares of restricted common stock on September 9, 2026 at $0.80 per share in connection with a private placement investment. Following this award, he directly holds 2,413,163 common shares.
On September 8, 2026 he also acquired a Common Stock Warrant covering 31,250 shares, with an exercise price of $1.10 per share and an expiration date of September 9, 2029. No Rule 10b5-1 trading plan is reported for these acquisitions.